X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3237) 3237
Publication (305) 305
Newsletter (138) 138
Book Review (51) 51
Book Chapter (9) 9
Dissertation (9) 9
Book / eBook (3) 3
Newspaper Article (3) 3
Magazine Article (2) 2
Conference Proceeding (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fluoxetine (2158) 2158
animals (1803) 1803
male (1657) 1657
pharmacology & pharmacy (1239) 1239
fluoxetine - pharmacology (1199) 1199
neurosciences (1150) 1150
rats (1130) 1130
humans (1049) 1049
index medicus (970) 970
psychiatry (878) 878
serotonin (801) 801
serotonin uptake inhibitors - pharmacology (695) 695
antidepressants (667) 667
female (656) 656
mice (607) 607
dose-response relationship, drug (524) 524
depression (507) 507
rats, sprague-dawley (417) 417
antidepressive agents - pharmacology (391) 391
serotonin antagonists - pharmacology (389) 389
adult (374) 374
brain (354) 354
serotonin - metabolism (346) 346
fluoxetine - therapeutic use (334) 334
rats, wistar (333) 333
antidepressant (332) 332
major depression (314) 314
depression, mental (300) 300
clinical neurology (287) 287
double-blind (276) 276
serotonin uptake inhibitors - therapeutic use (273) 273
middle aged (259) 259
behavior, animal - drug effects (256) 256
receptors (252) 252
5-ht (251) 251
disease models, animal (249) 249
research (248) 248
serotonin reuptake inhibitors (242) 242
anxiety (238) 238
drug interactions (238) 238
rat (236) 236
drugs (228) 228
motor activity - drug effects (228) 228
paroxetine (227) 227
antidepressive agents - therapeutic use (226) 226
analysis (213) 213
piperazines - pharmacology (206) 206
time factors (206) 206
dopamine (205) 205
depression - drug therapy (200) 200
rat-brain (198) 198
serotonin uptake inhibitors (195) 195
fluoxetine - administration & dosage (192) 192
depressive disorder - drug therapy (190) 190
fluoxetine - analogs & derivatives (190) 190
forced swimming test (190) 190
citalopram (182) 182
hippocampus (179) 179
brain - metabolism (177) 177
microdialysis (176) 176
brain - drug effects (173) 173
drug therapy (173) 173
treatment outcome (173) 173
hippocampus - drug effects (171) 171
rodents (170) 170
receptors, serotonin - drug effects (166) 166
neurons (164) 164
serotonin - physiology (164) 164
biochemistry & molecular biology (160) 160
drug therapy, combination (160) 160
in-vivo (160) 160
receptor (160) 160
serotonin receptor agonists - pharmacology (159) 159
behavioral sciences (158) 158
article (156) 156
sertraline (156) 156
antidepressive agents, second-generation - pharmacology (155) 155
stress (153) 153
behavior (151) 151
hippocampus - metabolism (149) 149
major depressive disorder (144) 144
mental depression (142) 142
mice, inbred c57bl (142) 142
serotonin uptake inhibitors - adverse effects (138) 138
placebo-controlled trial (136) 136
fluoxetine - adverse effects (134) 134
neurons - drug effects (134) 134
pyridines - pharmacology (132) 132
imipramine (130) 130
pharmacology (130) 130
prefrontal cortex (129) 129
5-hydroxytryptamine (128) 128
in vitro techniques (124) 124
analysis of variance (123) 123
double-blind method (123) 123
ssri (121) 121
expression (120) 120
fluvoxamine (120) 120
health aspects (120) 120
serotonin uptake inhibitors - administration & dosage (120) 120
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3341) 3341
French (13) 13
Russian (10) 10
German (8) 8
Spanish (8) 8
Japanese (5) 5
Chinese (3) 3
Polish (3) 3
Dutch (2) 2
Portuguese (2) 2
Hungarian (1) 1
Italian (1) 1
Norwegian (1) 1
Persian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Psychiatry, ISSN 1359-4184, 10/2014, Volume 19, Issue 10, pp. 1106 - 1114
Current antidepressants must be administered for several weeks to produce therapeutic effects. We show that selective serotonin 2C (5-HT2C) antagonists exert... 
Antidepressant | mTOR | BDNF | Neuronal remodeling | eEF | PATHWAYS | DEPRESSION | PSYCHIATRY | NEUROTROPHIC FACTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | antidepressant | INCREASES | neuronal remodeling | CHRONIC MILD STRESS | ELEMENT-BINDING PROTEIN | NEUROSCIENCES | CHRONIC FLUOXETINE | 5-HT2C RECEPTOR | ANIMAL-MODELS | OLFACTORY BULBECTOMIZED RATS | Citalopram - pharmacology | TOR Serine-Threonine Kinases - metabolism | Depressive Disorder - pathology | Prefrontal Cortex - physiopathology | Receptor, Serotonin, 5-HT2C - metabolism | Elongation Factor 2 Kinase - metabolism | Depressive Disorder - drug therapy | Prefrontal Cortex - pathology | Receptors, Dopamine D1 - metabolism | Prefrontal Cortex - drug effects | Time Factors | Female | Antidepressive Agents - pharmacology | Brain-Derived Neurotrophic Factor - metabolism | Pyramidal Cells - drug effects | Disease Models, Animal | Receptors, Dopamine D1 - antagonists & inhibitors | Olfactory Bulb - physiopathology | Pyramidal Cells - physiopathology | Serotonin 5-HT2 Receptor Antagonists - pharmacology | Animals | Depressive Disorder - physiopathology | Cyclic AMP Response Element-Binding Protein - metabolism | Pyramidal Cells - pathology | Stress, Psychological | Mice, Inbred BALB C | Serotonin Uptake Inhibitors - pharmacology | Chronic Disease | Antagonists (Biochemistry) | Usage | Serotonin | Antidepressants | Depression, Mental | Patient outcomes | Physiological aspects | Research | Drug therapy | Health aspects
Journal Article
Depression and Anxiety, ISSN 1091-4269, 10/2016, Volume 33, Issue 10, pp. 895 - 906
Kappa‐opioid receptor (KOR) antagonists are currently being considered for the treatment of a variety of neuropsychiatric conditions, including depressive,... 
anxiety | treatment | anxiety disorders | mood disorders | pharmacotherapy | substance use disorders | CREB PHOSPHORYLATION | PSYCHIATRY | RATS | COCAINE REWARD | ELEMENT-BINDING PROTEIN | RECEPTOR-AGONIST SALVINORIN | FORCED SWIM TEST | PSYCHOLOGY, CLINICAL | PSYCHOLOGY | INTRACRANIAL SELF-STIMULATION | ACUTE FLUOXETINE | BUPRENORPHINE | NUCLEUS-ACCUMBENS SHELL | Humans | Dynorphins - physiology | Dynorphins - therapeutic use | CREB-Binding Protein - genetics | Anti-Anxiety Agents - therapeutic use | Anxiety Disorders - drug therapy | Disease Models, Animal | Nucleus Accumbens - physiopathology | Receptors, Opioid, kappa - antagonists & inhibitors | Brain - physiopathology | Translational Medical Research | Gene Expression Regulation - physiology | Substance-Related Disorders - physiopathology | Substance-Related Disorders - complications | Antidepressive Agents - therapeutic use | Brain - drug effects | Gene Expression Regulation - drug effects | Receptors, Opioid, kappa - physiology | Animals | Narcotic Antagonists - therapeutic use | Reward | Nucleus Accumbens - drug effects | Anxiety Disorders - physiopathology | Stress, Psychological - complications | Stress, Psychological - physiopathology | Clinical trials | Substance abuse | Anxiety | Stress (Psychology) | Antidepressants | Protein binding | Narcotics | Rodents
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 12/2007, Volume 323, Issue 3, pp. 838 - 845
Journal Article
Journal Article
PLoS neglected tropical diseases, ISSN 1935-2735, 08/2019, Volume 13, Issue 8, p. e0007573
Journal Article
Neuropharmacology, ISSN 0028-3908, 08/2013, Volume 71, pp. 83 - 97
Serotonin (5-HT) is a neurotransmitter that is involved in many behavioral functions, including the organization of defense, and its putative pathological... 
Fear | Zebrafish | Anxiety | Serotonin | Scototaxis | Geotaxis | 5-HYDROXYTRYPTAMINE RELEASE | RAT | 5-HT1A RECEPTOR ANTAGONISTS | REUPTAKE INHIBITORS | DORSAL RAPHE | ADULT ZEBRAFISH | ELEVATED PLUS-MAZE | T-MAZE | NEUROSCIENCES | IN-VIVO | PHARMACOLOGY & PHARMACY | BRAIN | Anti-Anxiety Agents - administration & dosage | Fenclonine - administration & dosage | Spiro Compounds - therapeutic use | Anxiety - drug therapy | Piperidones - therapeutic use | Serotonin - chemistry | Brain - metabolism | Pyridines - adverse effects | Fenclonine - adverse effects | Behavior, Animal - drug effects | Hyperkinesis - chemically induced | Neurons - metabolism | Serotonin 5-HT1 Receptor Antagonists - administration & dosage | Anti-Anxiety Agents - therapeutic use | Buspirone - therapeutic use | Fluoxetine - adverse effects | Disease Models, Animal | Pyridines - administration & dosage | Nerve Tissue Proteins - agonists | Piperazines - therapeutic use | Piperazines - adverse effects | Extracellular Fluid - drug effects | Brain - drug effects | Serotonin Uptake Inhibitors - administration & dosage | Fluoxetine - administration & dosage | Piperazines - administration & dosage | Fenclonine - therapeutic use | Spiro Compounds - administration & dosage | Piperidones - adverse effects | Hyperkinesis - metabolism | Spiro Compounds - adverse effects | Dose-Response Relationship, Drug | Buspirone - administration & dosage | Protein Isoforms - metabolism | Protein Isoforms - agonists | Anti-Anxiety Agents - adverse effects | Buspirone - adverse effects | Fluoxetine - therapeutic use | Neurons - drug effects | Anxiety - metabolism | Pyridines - therapeutic use | Nerve Tissue Proteins - antagonists & inhibitors | Serotonin Uptake Inhibitors - therapeutic use | Serotonin Uptake Inhibitors - adverse effects | Serotonin 5-HT1 Receptor Agonists - therapeutic use | Serotonin 5-HT1 Receptor Agonists - adverse effects | Serotonin 5-HT1 Receptor Antagonists - adverse effects | Nerve Tissue Proteins - metabolism | Piperidones - administration & dosage | Extracellular Fluid - metabolism | Serotonin 5-HT1 Receptor Antagonists - therapeutic use | Animals | Serotonin - metabolism | Serotonin 5-HT1 Receptor Agonists - administration & dosage | Anxiety - chemically induced | Protein Isoforms - antagonists & inhibitors | Phenols | Buspirone hydrochloride | Fluoxetine
Journal Article
Journal Article
Progress in Neuropsychopharmacology & Biological Psychiatry, ISSN 0278-5846, 2008, Volume 32, Issue 2, pp. 380 - 386
Journal Article